Primary breast lymphoma (PBL) should be distinguished from secondary breast lymphoma arising in the setting of lymphoma elsewhere in the body. Multimodality imaging is key to diagnosing PBL, and imaging manifestations thereof may indicate PBL and alter the treatment course. Treatment options including chemotherapy, radiation therapy, and/or surgery depend on histology. We report two cases of PBL, illustrating the transformative impact that multimodality imaging may have on clinical management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683364 | PMC |
| http://dx.doi.org/10.1016/j.clinimag.2020.08.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A practical distribution pattern of α-SMA-positive carcinoma associated fibroblasts indicates poor prognosis of patients with pancreatic ductal adenocarcinoma.
Transl Oncol
January 2025
Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Naval Medical University (Second Military Medical University), 168 Changhai Road, Shanghai 200433, China. Electronic address:
Purpose The present study aimed to clarify the distribution pattern of carcinoma associated fibroblasts (CAFs) across pancreatic ductal adenocarcinoma (PDAC) and its prognostic prediction value. Methods Data of two cohorts were retrospectively collected from consecutive patients who underwent primary pancreatic resection from January 2015 to December 2017. We used tumor specimens to screen out the most suitable markers for the spatial distribution analysis for CAFs subpopulations.
View Article and Find Full Text PDFA Neurocysticercosis Case from Timor-Leste, A Previously Unidentified Region of Human Taeniasis Endemicity.
Am J Trop Med Hyg
January 2025
Department of Environmental Biology & Medical Parasitology, Hanyang University College of Medicine, Seoul, Republic of Korea.
Neurocysticercosis, a central nervous system infection caused by the zoonotic parasite Taenia solium, is a leading cause of acquired epilepsy worldwide. It is common in areas with extensive pig farming and pork consumption. This report presents an unusual case of neurocysticercosis in a 28-year-old male from Timor-Leste, a region of nonendemicity for human cases of Taenia solium.
View Article and Find Full Text PDFHow people respond to their analgesic adverse drug event: A secondary data analysis.
J Am Assoc Nurse Pract
September 2024
Hashemite University, Zarqa, Jordan.
Background: An individual's inability to self-identify or refusal to acknowledge an analgesic adverse drug event (ADE) lengthens the time to ADE treatment and resolution and may worsen the outcome.
Purpose: The purpose was to describe how people who experienced an analgesic ADE during pain self-management respond to the event and to identify predictors of serious analgesic ADEs.
Methodology: The design was a secondary data analysis.
Vertebral Column Subluxation in Neurofibromatosis Type 1-Associated Dystrophic Scoliosis: A Report of Two Cases and Narrative Review.
Oper Neurosurg (Hagerstown)
September 2024
Department of Neurosurgery, New York University, New York, New York, USA.
Background And Objective: Neurofibromatosis-1 (NF1) dystrophic scoliosis is a challenging disease to manage surgically, with multiplanar curves progressing rapidly and unpredictably. Conservative management with bracing is often unsuccessful, and many patients necessitate instrumented fusion to halt progression of their curves. In rare cases, patients can present with spontaneous vertebral subluxation, significantly complicating the surgical management of this already complex disease process.
View Article and Find Full Text PDFClinical efficacy of pyrotinib combined with chemotherapy for neoadjuvant treatment in HER2-positive breast cancer: a single-center study.
Anticancer Drugs
January 2025
Department of Breast Surgery, the First People's Hospital of Lianyungang, The Affiliated Hospital of XuZhou Medical University, Lianyungang, Jiangsu Province, China.
This study aimed to evaluate the efficacy of pyrotinib, an orally administered small molecule tyrosine kinase inhibitor, combined with neoadjuvant chemotherapy in treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Pyrotinib works by inhibiting the HER2 signaling pathway, thereby preventing tumor cell growth. This single-arm clinical trial aimed to assess the total pathological complete response (tpCR; ypT0/is and ypN0) rate as the primary endpoint.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!